Cargando…

Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E

Chemoresistance has become a primary hurdle in the therapeutic outcome of hepatocellular carcinoma. Substantial evidences have demonstrated that microRNAs (miRNAs) are closely associated with the chemoresistance of hepatocellular carcinoma (HCC). Our investigation is aimed at testifying the influenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ying, Tie, Qingsong, Bao, Zhiwei, Shao, Zhi, Zhang, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605919/
https://www.ncbi.nlm.nih.gov/pubmed/34812269
http://dx.doi.org/10.1155/2021/6468405
_version_ 1784602251384324096
author Zhang, Ying
Tie, Qingsong
Bao, Zhiwei
Shao, Zhi
Zhang, Lan
author_facet Zhang, Ying
Tie, Qingsong
Bao, Zhiwei
Shao, Zhi
Zhang, Lan
author_sort Zhang, Ying
collection PubMed
description Chemoresistance has become a primary hurdle in the therapeutic outcome of hepatocellular carcinoma. Substantial evidences have demonstrated that microRNAs (miRNAs) are closely associated with the chemoresistance of hepatocellular carcinoma (HCC). Our investigation is aimed at testifying the influence of microRNA-15a-5p (miR-15a-5p)/eukaryotic translation initiation factor 4E (eIF4E) on hepatocellular carcinoma resistance to pirarubicin (THP). In our study, miR-15a-5p expression was increased in THP-treated HepG2 cells. Downregulation of miR-15a-5p blocked cell growth and elevated cell apoptosis of HepG2 cells treated with THP. Moreover, eIF4E was verified as a direct target of miR-15a-5p by binding its 3′-UTR, which was confirmed by luciferase report experiment. Additionally, eIF4E was negatively associated with the miR-15a-5p expression in HepG2 cells. Mechanically, eIF4E was proven as a specific downstream of miR-15a-5p and mediated the effects of miR-15a-5p on cell viability and apoptosis of HepG2 cells treated with THP. These findings supported that miR-15a-5p facilitated THP resistance of hepatocellular carcinoma cells by modulating eIF4E, thus providing an experimental basis that miR-15a-5p might act as a novel diagnostic target in hepatocellular carcinoma resistance to THP.
format Online
Article
Text
id pubmed-8605919
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-86059192021-11-21 Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E Zhang, Ying Tie, Qingsong Bao, Zhiwei Shao, Zhi Zhang, Lan Comput Math Methods Med Research Article Chemoresistance has become a primary hurdle in the therapeutic outcome of hepatocellular carcinoma. Substantial evidences have demonstrated that microRNAs (miRNAs) are closely associated with the chemoresistance of hepatocellular carcinoma (HCC). Our investigation is aimed at testifying the influence of microRNA-15a-5p (miR-15a-5p)/eukaryotic translation initiation factor 4E (eIF4E) on hepatocellular carcinoma resistance to pirarubicin (THP). In our study, miR-15a-5p expression was increased in THP-treated HepG2 cells. Downregulation of miR-15a-5p blocked cell growth and elevated cell apoptosis of HepG2 cells treated with THP. Moreover, eIF4E was verified as a direct target of miR-15a-5p by binding its 3′-UTR, which was confirmed by luciferase report experiment. Additionally, eIF4E was negatively associated with the miR-15a-5p expression in HepG2 cells. Mechanically, eIF4E was proven as a specific downstream of miR-15a-5p and mediated the effects of miR-15a-5p on cell viability and apoptosis of HepG2 cells treated with THP. These findings supported that miR-15a-5p facilitated THP resistance of hepatocellular carcinoma cells by modulating eIF4E, thus providing an experimental basis that miR-15a-5p might act as a novel diagnostic target in hepatocellular carcinoma resistance to THP. Hindawi 2021-11-13 /pmc/articles/PMC8605919/ /pubmed/34812269 http://dx.doi.org/10.1155/2021/6468405 Text en Copyright © 2021 Ying Zhang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zhang, Ying
Tie, Qingsong
Bao, Zhiwei
Shao, Zhi
Zhang, Lan
Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E
title Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E
title_full Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E
title_fullStr Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E
title_full_unstemmed Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E
title_short Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E
title_sort inhibition of mir-15a-5p promotes the chemoresistance to pirarubicin in hepatocellular carcinoma via targeting eif4e
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605919/
https://www.ncbi.nlm.nih.gov/pubmed/34812269
http://dx.doi.org/10.1155/2021/6468405
work_keys_str_mv AT zhangying inhibitionofmir15a5ppromotesthechemoresistancetopirarubicininhepatocellularcarcinomaviatargetingeif4e
AT tieqingsong inhibitionofmir15a5ppromotesthechemoresistancetopirarubicininhepatocellularcarcinomaviatargetingeif4e
AT baozhiwei inhibitionofmir15a5ppromotesthechemoresistancetopirarubicininhepatocellularcarcinomaviatargetingeif4e
AT shaozhi inhibitionofmir15a5ppromotesthechemoresistancetopirarubicininhepatocellularcarcinomaviatargetingeif4e
AT zhanglan inhibitionofmir15a5ppromotesthechemoresistancetopirarubicininhepatocellularcarcinomaviatargetingeif4e